



Australian Government



Information on COVID-19 Pfizer (Comirnaty) vaccine

About the vaccine

Comirnaty (Pfizer Australia Pty Ltd) is a vaccine that can prevent people from becoming ill from COVID-19. Comirnaty does not contain any live virus, and it cannot give you COVID-19. It contains the genetic code for an important part of the SARS-CoV-2 virus called the spike protein. After getting the vaccine, your body makes copies of the spike protein, and your immune system will learn to recognise and fight against the SARS-CoV-2 virus, which causes COVID-19.

To prevent COVID-19, everyone aged 16 years and older should get vaccinated, with a few exceptions specified in this information sheet. Vaccination is voluntary.


You can discuss any concerns or questions you have about COVID-19 vaccination with your immunisation provider and/or your GP before you receive the vaccine.

Benefits of the vaccine

A very large clinical trial showed that Comirnaty is effective in preventing COVID-19 in people aged 16 years and older. People who had two doses of Comirnaty were about 95 per cent less likely to get COVID-19 than people who did not get the vaccine. It was equally effective in people over the age of 65 years, and as people with some stable pre-existing medical conditions.

Protection against COVID-19 starts from about 2–3 weeks after the first dose. While one dose may give some protection, it may only last for the short-term. Two doses will give optimal protection. No vaccine is 100 per cent effective, so it is possible that you can still get sick from COVID-19 after vaccination. We do not know how long the protection from Comirnaty will last. We will learn more about this over time.

We currently do not know how effective COVID-19 vaccines are at preventing spread of the virus. This means that SARS-CoV-2 could potentially still infect a vaccinated person. Even if they have no symptoms or only mild symptoms they could still pass it on to others.



This is why it is important to continue other preventative measures like:

- physical distancing
- hand washing
- wearing a face mask
- COVID-19 testing and quarantine/isolation as required by your state/territory.

If you have been vaccinated with two doses of Comirnaty, you should still get a COVID-19 test if you have symptoms that meet testing criteria according to your local health authority (e.g. fever, cough, sore throat).

Who can receive this vaccine

People aged 16 years and older can receive this COVID-19 vaccination.

Certain groups of people are prioritised to receive vaccines first because they are at higher risk of exposure to the COVID-19 virus (e.g. workers in border or quarantine facilities, a healthcare facility or aged-care facility) or severe illness and death from COVID-19 (e.g. are older or have underlying medical conditions).

Who should not receive this vaccine

You should not receive this vaccine if you have had:

- anaphylaxis (a type of severe allergic reaction) to a previous dose of the same COVID-19 vaccine, or
- anaphylaxis after exposure to any component of a COVID-19 vaccine.

Precautions for vaccination

If **you have a history of anaphylaxis** (a type of severe allergic reaction) to any substance, or you **have an adrenaline autoinjector** (e.g. an EpiPen), you will need to stay for 30 minutes of observation after you have your vaccine. In the very rare cases where severe allergic reactions were reported after Comirnaty, these reactions usually occurred in the first 30 minutes after vaccination.

If **you have a bleeding disorder** or you are **taking a blood-thinning medication** (anticoagulant), tell your immunisation provider. Your immunisation provider can help determine whether it is safe for you to have an intramuscular injection, and to decide the best timing for injection.

Special circumstances to discuss before vaccination

People with weakened immune systems (immunocompromise)

People with immunocompromise includes those who have a medical condition that weakens their immune system or may be taking medications that suppress their immune system.

The Australian Government strongly recommends people with immunocompromise receive COVID-19 vaccination. Comirnaty is not a live vaccine. It is safe in people with immunocompromise.

People with immunocompromise, including those living with HIV, have a higher risk of severe illness from COVID-19, including a higher risk of death.

Clinical trials for Comirnaty did not include people with immunocompromise, except for a small group of people with stable HIV. We do not know if Comirnaty is as effective in people with immunocompromise compared to the rest of the population. It is possible that Comirnaty might not be as effective in people with immunocompromise as it is in the general population. It is

important to continue other preventative measures such as physical distancing after vaccination.

Women who are pregnant, breastfeeding or planning pregnancy

If you are breastfeeding, you can have Comirnaty. You do not need to stop breastfeeding after vaccination. If you are planning pregnancy, you can also have Comirnaty. You do not need to have a pregnancy test before vaccination.

Pregnant women are not routinely recommended to have Comirnaty, but can consider vaccination particularly if they are at higher risk of getting COVID-19 e.g. due to their occupation, or if they have risk factors for severe illness, e.g. due to pre-existing medical conditions.

If you are pregnant, your healthcare provider can help you to assess the benefits and risks of vaccination.

People with a history of COVID-19

If you have had COVID-19, tell your immunisation provider. Your provider may advise to wait for up to six months before having a COVID-19 vaccine.

Comirnaty and children

Comirnaty has only been provisionally approved for use in people aged 16 years or older, and cannot be given to younger people. Clinical trials are currently testing Comirnaty in older children, but we do not yet have the results of this trial. The risk of COVID-19, especially severe disease, in children is lower than in older adolescents and adults.

Ensuring the safety of Comirnaty

Increased funding for vaccine research, and access to very large numbers of volunteers for research studies have meant Comirnaty and other COVID-19 vaccines have been developed quickly. A large clinical trial involving around 44,000 people confirmed Comirnaty to be safe and effective.

The Therapeutic Goods Administration (TGA) assesses all vaccines in Australia. This ensures that in order for a vaccine to be approved it is safe, effective and manufactured to a very high quality standard. A description of the process for approval of COVID-19 vaccines is available on the [TGA website](#).

The safety of COVID-19 vaccines will be monitored continuously throughout the COVID-19 vaccination program. Suspected side effects can be reported to your vaccination provider or other healthcare professional. They will then make a formal report on your behalf to your state or territory health department or directly to the Therapeutic Goods Administration (TGA).

If you would prefer to report it yourself, please visit the [TGA website](#) for information on how to report suspected side effects associated with COVID-19 vaccines.